Compare Charles River Laboratories Intl. Inc (CRL) vs Invesco S&P 500 Momentum ETF (SPMO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Invesco S&P 500 Momentum ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $287.99 (market cap $13.46B), while Invesco S&P 500 Momentum ETF trades at $150.13. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Invesco S&P 500 Momentum ETF nearer its low. Which is the better fit depends on your goals.
| CRL | SPMO | |
|---|---|---|
Market Cap | $13.46B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $282.00 | $161.66 |
52-Week Low | $145.57 | $107.84 |
Enterprise Value | $16.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SPMO (Invesco S&P 500 Momentum ETF) trades at $149.69, up 0.4% with strong bullish momentum indicators. The ETF has demonstrated exceptional 2026 performance with 26% returns, significantly outperforming the S&P 500 while maintaining lower drawdowns. Technical analysis shows bullish moving averages but neutral oscillators, with RSI_6 at 88.22 suggesting potential overbought conditions. Recent institutional interest includes Alpha Zero LLC increasing its position by 6.4% to $10.73 million in Q1 2026.
The outlook remains positive given SPMO's momentum-driven strategy and concentrated tech exposure (55% weighting), particularly benefiting from AI-driven growth. However, risks include higher volatility during sector rotations and downside vulnerability if momentum factors reverse. The ETF's 0.13% expense ratio provides cost efficiency for momentum exposure, but investors should monitor concentration risks in technology holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →
